Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multi-dose study of SGN-30 in refractory or recurrent Hodgkin disease or anaplastic large cell lymphoma
2005-003369-17Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iratumumab in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Apr 2007; status: completed.
02
Drugs
iratumumab
03
Conditions
Hodgkin lymphoma (HL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on 2005-003369-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003369-17.